Original Research
Published on 10 Mar 2023
LIM1 contributes to the malignant potential of endometrial cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1082441
- 2,315 views
- 2 citations
Type at least 3 characters
1,765 articles
Articles
Original Research
Published on 08 Mar 2023
PSGL-1 is a novel tumor microenvironment prognostic biomarker with cervical high-grade squamous lesions and more
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1052201
- 2,381 views
- 6 citations
Review
Published on 07 Mar 2023
Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1071030
- 3,584 views
- 7 citations
Original Research
Published on 07 Mar 2023
JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1126482
- 2,776 views
- 3 citations
Systematic Review
Published on 03 Mar 2023
Prognostic value of nectin-4 in human cancers: A meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1081655
- 3,962 views
- 6 citations
Original Research
Published on 03 Mar 2023
Identification of the novel therapeutic targets and biomarkers associated of prostate cancer with cancer-associated fibroblasts (CAFs)
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1136835
- 3,812 views
- 8 citations
Original Research
Published on 28 Feb 2023
Metabolic classification of non-small cell lung cancer patient-derived xenografts by a digital pathology approach: A pilot study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1070505
- 1,954 views
- 1 citation
Original Research
Published on 27 Feb 2023
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1124039
- 5,856 views
- 9 citations
Original Research
Published on 27 Feb 2023
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1104659
- 1,985 views
- 4 citations
Original Research
Published on 23 Feb 2023
Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1127517
- 4,314 views
- 5 citations
Original Research
Published on 23 Feb 2023
Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.819357
- 2,004 views
- 5 citations
Original Research
Published on 23 Feb 2023
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.860711
- 3,533 views
- 2 citations
Original Research
Published on 22 Feb 2023
The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1124517
- 1,636 views
- 4 citations
Case Report
Published on 22 Feb 2023
Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1126325
- 2,423 views
- 2 citations
Mini Review
Published on 20 Feb 2023
ARID1A in cancer: Friend or foe?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1136248
- 10,869 views
- 13 citations
Review
Published on 16 Feb 2023
Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1064616
- 3,288 views
- 4 citations